WYE-23

Catalog No. :
ACDCXS115
CAS No. :
1062169-46-3
Molecular Formula :
C26H32N8O4
Molecular Weight :
520.59

IUPAC Name:methyl 4-(6-(4-(3-cyclopropylureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate

WYE-23 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg97%$222.00Login to see priceInquiryInquiry
5mg97%$696.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameWYE-23
IUPAC Namemethyl 4-(6-(4-(3-cyclopropylureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate
Molecular FormulaC26H32N8O4
Molecular Weight520.59
SMILESO=C(N1CCC(N2N=CC3=C(N4CCOCC4)N=C(C5=CC=C(NC(NC6CC6)=O)C=C5)N=C32)CC1)OC
InChI KeyNQNFBVOZVJAWSQ-UHFFFAOYSA-N
SynonymCompound 23;mTOR Inhibitor, WYE-23;methyl 4-(6-(4-[(cyclopropylcarbamoyl)amino]phenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate;WYE-23;1-Piperidinecarboxylic acid, 4-[6-[4-[[(cyclopropylamino)carbonyl]amino]phenyl]-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-, methyl ester;4-[6-[4-[[(cyclopropylamino)carbonyl]amino]phenyl]-4-(4-morpholinyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinecarboxylicacid,methylester
CAS No.1062169-46-3

Synthetic Route by SureRoute

1. ACDCXS115 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDCXS115 route product structure diagram
    ACDCXS1151062169-46-3
Inquiry

2. ACDCXS115 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACPLAD840 route compound structure diagram
    ACPLAD840874297-79-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACDCXS115 route product structure diagram
    ACDCXS1151062169-46-3
Inquiry

Comments (0)